Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038506 | 0.77 | HDAC1 (0.39) | PTGES2ENPP2 | |
| SCHEMBL1542154 | 0.75 | ALPL (0.52) | PTGES2PTPN1ALPLHSD17B1HSD17B2 | |
| SCHEMBL29843178 | 0.75 | ALPL (0.52) | PTGES2PTPN1ALPLHSD17B1HSD17B2 | |
| SCHEMBL2326796 | 0.74 | EPHX2 (0.49) | — | |
| SCHEMBL5527636 | 0.73 | HDAC6 (0.38) | PKM | |
| SCHEMBL2327744 | 0.73 | SCN9A (0.39) | SCN9A | |
| SCHEMBL5628428 | 0.72 | CDC25B (0.45) | PKM | |
| SCHEMBL4407236 | 0.72 | HDAC1 (0.45) | — | |
| SCHEMBL4619724 | 0.71 | CA1 (0.35) | PKM | |
| SCHEMBL28856969 | 0.70 | CA2 (0.41) | PTGES2PTPN1ALPLENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| CN-101522646-A | Oxadiazole derivatives having anti-inflammatory and immunosuppressive properties | NOVARTIS AG (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2081916-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | Novartis AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037476-A1 | OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087491-A1 | POLYCYCLIC COMPOUNDS | CD4, HLA-DRB1, MALT1 | MRGPRX1 371/4885PTGES2 1147/4885PTPN1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.